Genetic risk test for melanoma (AnteMEL)

• analyzes of 28 genetic variants associated with melanoma;
• individual polygenic risk score for melanoma;
• the individual risk of melanoma compared to the rest of the population;
• likelihood to get melanoma in 10 years and risk assessment compared to a person with average genetic risk;
• interpretation of the test results with clinical recommendations.

• AnteMEL test is not used to diagnose melanoma;
• AnteMEL test is not validated for use by individuals of non-European descent;
• An elevated risk estimated by the AnteMEL test does not mean that you will develop melanoma during their lifetime. Also, a moderate or lower risk does not mean that the probability of developing the diseases is zero;
• AnteMEL test does not assess the risk of your family and relatives, i.e. polygenic risk score-based disease risks may not be transmitted directly from parents to children;
• AnteMEL test does not analyze rare pathogenic mutations in genes that significantly increase the risk of melanoma, such as CDKN2A, MC1R, CDK4, TP53, PTEN, BAP1, POT1, ACD, PARK2, TERF2IP, TERT, BRCA1, BRCA2, RB1;
• the AnteMEL test is based on the most up-to-date scientific data, which may, however, be supplemented and changed in the future as additional information becomes available. The field of genetics is constantly evolving, which may lead to changes in risk assessments over time, as well as changes in test selection recommendations and clinical recommendations based on test results;
• Different polygenic risk scores predicting risks of the same trait may give different estimates of the individual’s risks due to differences in the genetic variants included in the models and their weights;
• The results of this test should be applied in context with other relevant clinical data. In addition to the possible genetic predisposition, other risk factors also influence the risk of skin melanoma.